News

Artis News

All Press Release Artis BioSolutions Cell & Gene Therapy DNA Syngoi GMP Grant ARPA-H

Artis BioSolutions Launches mRNA and Lipid Nanoparticle Manufacturing Capabilities at New Genetic Medicines Center of Excellence

Press Release · August 26, 2026

New center integrates synthetic DNA, mRNA, targeted delivery, and GMP drug product capabilities to help innovators advance genetic medicines from early development through...

Press Release Artis BioSolutions

Landmark Bio and Syngoi Technologies to Operate as Artis BioSolutions, an End-to-end Gene-to-GMP Platform for Genetic Medicines

Press Release

July 29, 2026

Rebrand unifies U.S. and European operations under a single Artis brand, connecting synthetic DNA starting material to...

Cell & Gene Therapy

Landmark Bio Forges New Collaboration to Accelerate Early-Stage Translational Cell and Gene Therapies

Press Release

May 02, 2026

Agreement establishes framework for advancing Mass General Brigham-originated cell and gene therapies

Landmark Bio to support...

DNA Syngoi GMP

Artis BioSolutions Announces Agreement to Acquire Syngoi Technologies to Deliver Next Generation Solutions for Synthetic DNA Technology

Press Release

May 02, 2026

SAN DIEGO & BOSTON & BILBAO, Spain--(BUSINESS WIRE)--Artis BioSolutions (“Artis”), a San Diego-based advanced-therapies...

DNA Syngoi GMP

Artis BioSolutions Establishes U.S.-based Synthetic DNA Manufacturing Hub in Boston

Press Release

May 02, 2026

WATERTOWN, Mass.--(BUSINESS WIRE)--Landmark Bio, an Artis BioSolutions company dedicated to accelerating the translation of...

Grant ARPA-H

Landmark Bio Secures Up to $18.3 Million ARPA-H Award to Build a Scalable Continuous Manufacturing Platform for Extracellular Vesicle Therapies

Press Release

May 01, 2026

WATERTOWN, Mass.--(BUSINESS WIRE)--Landmark Bio, an Artis BioSolutions company dedicated to accelerating the translation of...